RESUMEN
BACKGROUND: Tumor necrosis factor alpha, interleukin 6 and 1 have a pathogenic role in Crohn's disease. Infliximab, a monoclonal antibody against tumor necrosis factor, is useful in the treatment of Crohn's disease, specially when the disease is active and associated to fistula formation. AIM: To assess the effectiveness of Infliximab in patients with Crohn's disease. MATERIAL AND METHODS: Twelve patients with Crohn's disease (aged 16 to 63 years, 10 women) refractory to treatment with steroid, 5-aminosalicylic acid, antimicrobials and immunomodulatory drugs, were studied. A single intravenous 5 mg/kg dose Infliximab was administered. The Crohn's disease activity index (CDAI) was measured before and one week after the administration of the drug. RESULTS: CDAI before and after Infliximab administration was 357+/-62 and 138+/-122 score points, respectively (p <0.005). According to this score, five patients had a severe and seven a moderate disease flare. The disease remitted in 7 (58%) and a clinical response was observed in 75%. CONCLUSIONS: A single dose of Infliximab was effective to induce remission of the disease in 75% of this selected group of patients with Crohn's disease.
Asunto(s)
Anticuerpos Monoclonales/uso terapéutico , Enfermedad de Crohn/tratamiento farmacológico , Fármacos Gastrointestinales/uso terapéutico , Adolescente , Adulto , Femenino , Humanos , Infliximab , Masculino , Persona de Mediana Edad , Estudios Retrospectivos , Índice de Severidad de la Enfermedad , Resultado del TratamientoRESUMEN
Background: Tumor necrosis factor alpha, interleukin 6 and 1 have a pathogenic role in Crohn's disease. Infliximab, a monoclonal antibody against tumor necrosis factor, is useful in the treatment of Crohn's disease, specially when the disease is active and associated to fistula formation. Aim: To assess the effectiveness of Infliximab in patients with Crohn's disease. Material and methods: Twelve patients with Crohn's disease (aged 16 to 63 years, 10 women) refractory to treatment with steroid, 5-aminosalicylic acid, antimicrobials and immunomodulatory drugs, were studied. A single intravenous 5 mg/kg dose Infliximab was administered. The Crohn's disease activity index (CDAI) was measured before and one week after the administration of the drug. Results: CDAI before and after Infliximab administration was 357±62 and 138±122 score points, respectively (p <0.005). According to this score, five patients had a severe and seven a moderate disease flare. The disease remitted in 7 (58%) and a clinical response was observed in 75%. Conclusions: A single dose of Infliximab was effective to induce remission of the disease in 75% of this selected group of patients with Crohn's disease.
Asunto(s)
Adolescente , Adulto , Femenino , Humanos , Masculino , Persona de Mediana Edad , Anticuerpos Monoclonales/uso terapéutico , Enfermedad de Crohn/tratamiento farmacológico , Fármacos Gastrointestinales/uso terapéutico , Estudios Retrospectivos , Índice de Severidad de la Enfermedad , Resultado del TratamientoRESUMEN
Introducción: La adolescencia es un período donde el individuo es susceptible a adquirir un trastorno psicológico. La depresión en adolescentes es prevalente, con repercusiones en múltiples ámbitos, siendo una importante causa de morbimortalidad. Este trabajo busca determinar la prevalencia y distribución de síntomas depresivos y su posible asociación al antecedente de consulta previa a profesional de la salud. Método: Fue aplicada la versión traducida al español del Inventario de Beck, en adolescentes de 12 a 18 años de dos colegios privados del sector oriente de Santiago de Chile. Resultados: De un total de 363 alumnos, presentaron síntomas depresivos un 13,8 por ciento de la población, con un 19,8 por ciento en mujeres y 7,4 por ciento en hombres (p< 0,001). No existió diferencia estadística entre los grupos etarios. Los síntomas depresivos se asociaron con la consulta previa (p< 0,001). Discusión: Las cifras obtenidas son similares a las encontradas en la literatura. Los síntomas depresivos son prevalentes, más frecuentes en mujeres y están asociados a la consulta previa. No podemos diferenciar si estos síntomas se pueden atribuir a la propia etapa de la adolescencia o a una psicopatología, por lo que sería interesante seguir estos alumnos en el tiempo junto con ampliar la muestra.